What's Going On With Heartbeam (BEAT) Stock?
What's Going On With Heartbeam (BEAT) Stock?
Heartbeam Inc (NASDAQ:BEAT) shares are trading higher by 3.5% to $2.35 Tuesday, pulling back following the session high of $2.70. The earlier move higher came despite a lack of company-specific news for the session.
周二，Heartbeam Inc（纳斯达克股票代码：BEAT）股价上涨3.5％，至2.35美元，在盘中高点2.70美元后回落。尽管该交易日缺乏公司具体消息，但早些时候还是出现了走高。
The company last week said it secured two new patents from the United States Patent and Trademark Office for its vectorelectrocardiography (VECG) technology, bringing its total to 14 issued US patents and 4 international patents.
该公司上周表示，其矢量心电图（VECG）技术获得了美国专利和商标局的两项新专利，使其已颁发的美国专利和4项国际专利总数达到14项。
The VECG technology collects 3D signals of the heart and converts them into a 12-lead ECG. These patents reinforce HeartBeam's commitment to transforming cardiac care by enabling personalized insights through portable, patient-friendly devices such as credit-card sized systems, extended wear patches or watches.
VECG 技术收集心脏的 3D 信号，并将其转换为 12 导联心电图。这些专利通过便携式、便于患者的设备（例如信用卡大小的系统、长效磨损贴片或手表）提供个性化见解，从而强化了HeartBeam对改变心脏护理的承诺。
The first patent focuses on a mobile three-lead cardiac monitoring device and method for automated diagnostics, aiding in the detection of heart attacks. The second patent covers HeartBeam's wrist-based ECG system, which combines continuous monitoring with the ability to take a high sensitivity 12-lead ECG.
第一项专利侧重于一种移动式三导心脏监测设备和自动诊断方法，有助于检测心脏病发作。第二项专利涵盖了HeartBeam的手腕式心电图系统，该系统将持续监测与拍摄高灵敏度12导联心电图的能力相结合。
Is BEAT A Good Stock To Buy?
BEAT 是一只值得买入的好股票吗？
An investor can make a few decisions when deciding whether a stock is a good buy. In addition to valuation metrics and price action which you can find on Benzinga's quote pages – like HeartBeam's page for example – there are factors like whether or not a company pays a dividend or buys a large portion of its stock each quarter.
投资者在决定股票是否值得买入时可以做出一些决定。除了可以在Benzinga的报价页面（例如HeartBeam的页面）上找到的估值指标和价格走势外，还有一些因素，例如公司是否每季度支付股息或购买大部分股票。
These are known as capital allocation programs. HeartBeam (NASDAQ:BEAT) does not pay a dividend, but obviously has a few ways it can return value to shareholders. Feel free to search Benzinga's dividend calendar for the next company that is due to pay a dividend and determine what kind of yield you can earn for holding a share of the company.
这些被称为资本分配计划。HeartBeam（纳斯达克股票代码：BEAT）不支付股息，但显然有几种方法可以向股东返还价值。您可以随时在Benzinga的股息日历中搜索下一家即将派发股息的公司，并确定持有该公司股份可以获得什么样的收益率。
Buyback programs are obviously different and highly variable. A company can approve a buyback program and purchase shares as it sees fit over the course of time in which the buyback was authorized. Looking through the latest news on HeartBeam will often yield whether or not the company has approved a buyback program recently. Buyback programs usually serve as a support for share prices, serving as a backstop for demand.
回购计划显然是不同的，而且变化很大。公司可以批准回购计划，并在回购获得批准的时间内酌情购买股票。浏览HeartBeam的最新消息通常可以得出该公司最近是否批准了回购计划。回购计划通常作为股价的支撑，作为需求的支撑。
According to data from Benzinga Pro, BEAT has a 52-week high of $3.74 and a 52-week low of $1.06.
根据Benzinga Pro的数据，BEAT的52周高点为3.74美元，52周低点为1.06美元。